SCHEMBL30455995

SCHEMBL30455995

CC(C)(C)OC(=O)N1CCC2(CC1)CN(c1ncnc3cnc(CC(F)(F)F)cc13)C2

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KIT P10721 2/20 0.42
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC2 Q92769 1/20 0.40
▸ CYP11B2 P19099 1/20 0.39
▸ ACACB O00763 4/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ SCD5 Q86SK9 1/20 0.38
▸ PARP1 P09874 3/20 0.38
▸ NAMPT P43490 1/20 0.37
▸ PIK3CA P42336 1/20 0.37
▸ MTOR P42345 1/20 0.37
▸ GPR119 Q8TDV5 1/20 0.37
▸ MAP4K4 O95819 1/20 0.36
▸ TNKS O95271 2/20 0.36
▸ TNKS2 Q9H2K2 2/20 0.36
▸ RET P07949 1/20 0.36
▸ JAK3 P52333 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30405237 0.86 KIT (0.44) KITHDAC1HDAC2CYP11B2MEN1
SCHEMBL25280892 0.86 KIT (0.44) KITHDAC1HDAC2CYP11B2MEN1
SCHEMBL30406325 0.85 KIT (0.41) KITHDAC1HDAC2CYP11B2ACACB
SCHEMBL30406086 0.84 KIT (0.44) KITHDAC1HDAC2CYP11B2MEN1
SCHEMBL30455880 0.83 MAP4K4 (0.47) KITHDAC1HDAC2CYP11B2ACACB
SCHEMBL25276952 0.82 KIT (0.42) KITHDAC1HDAC2CYP11B2ACACB
SCHEMBL30456403 0.81 ACACB (0.41) KITHDAC1HDAC2CYP11B2ACACB
SCHEMBL25232266 0.79 MAPK7 (0.47) KITHDAC1HDAC2CYP11B2GPR119
SCHEMBL30406372 0.79 KIT (0.49) KITCYP11B2PARP1GPR119MAP4K4
SCHEMBL30405719 0.79 MAPK7 (0.47) KITHDAC1HDAC2CYP11B2GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163061-A1 INHIBITORS OF MENIN-MLL INTERACTION BALA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-20250066358-A1 Inhibitors of Menin-MLL Interaction BALA THERAPEUTICS, INC. 2025-02-27 — — US disclosed
EP-4444313-A1 INHIBITORS OF MENIN-MLL INTERACTION Bala Therapeutics, Inc. (US) 2024-10-16 — — EP disclosed
WO-2023107687-A1 INHIBITORS OF MENIN-MLL INTERACTION BALA THERAPEUTICS, INC. (US) 2023-06-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163061-A1 INHIBITORS OF MENIN-MLL INTERACTION MLLT1, MEN1, BMI1 KIT 1067/4885HDAC1 158/4885HDAC2 241/4885
US-20250066358-A1 Inhibitors of Menin-MLL Interaction MLLT1, MEN1, BMI1 KIT 1067/4885HDAC1 158/4885HDAC2 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback